Literature DB >> 16201004

HIV vaccine research--South Africa's ethical-legal framework and its ability to promote the welfare of trial participants.

Ann Strode1, Catherine Slack, Muriel Mushariwa.   

Abstract

An effective ethical-legal framework for the conduct of research is critical. We describe five essential components of such a system, review the extent to which these components have been realised in South Africa, present brief implications for the ethical conduct of clinical trials of HIV vaccines in South Africa and make recommendations. The components of an effective ethical-legal system that we propose are the existence of scientific ethical and policy-making structures that regulate research; research ethics committees (RECs) that ethically review research; national ethical guidelines and standards; laws protecting research participants; and mechanisms to enforce and monitor legal rights and ethical standards. We conclude that the ethical-legal framework has, for the most part, the necessary institutions, and certain necessary guidelines but does not have many of the laws needed to protect and promote the rights of persons participating in research, including HIV vaccine trials. Recommendations made include advocacy measures to finalise and implement legislation, development of regulations, analysis and comparison of ethical guidelines, and the development of measures to monitor ethical-legal rights at trial sites.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16201004

Source DB:  PubMed          Journal:  S Afr Med J


  3 in total

1.  HIV incidence in young girls in KwaZulu-Natal, South Africa--public health imperative for their inclusion in HIV biomedical intervention trials.

Authors:  Quarraisha Abdool Karim; Ayesha B M Kharsany; Janet A Frohlich; Lise Werner; Mukelisiwe Mlotshwa; Bernadette T Madlala; Salim S Abdool Karim
Journal:  AIDS Behav       Date:  2012-10

2.  Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa.

Authors:  Jerome Amir Singh; Salim S Abdool Karim; Quarraisha Abdool Karim; Koleka Mlisana; Carolyn Williamson; Clive Gray; Michelle Govender; Andrew Gray
Journal:  PLoS Med       Date:  2006-04-18       Impact factor: 11.069

3.  The inhibition of the Human Immunodeficiency Virus type 1 activity by crude and purified human pregnancy plug mucus and mucins in an inhibition assay.

Authors:  Habtom H Habte; Corena de Beer; Zoë E Lotz; Marilyn G Tyler; Leann Schoeman; Delawir Kahn; Anwar S Mall
Journal:  Virol J       Date:  2008-05-19       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.